About Circassia Pharmaceuticals
Circassia Pharmaceuticals is a company based in Oxford (United Kingdom) founded in 2006 by Charles Swingland.. Circassia Pharmaceuticals has raised $156.6 million across 5 funding rounds from investors including Goldman Sachs, Invesco Perpetual and Imperial Innovations. The company has 128 employees as of December 31, 2021. Circassia Pharmaceuticals has completed 1 acquisition, including Prosonix. Circassia Pharmaceuticals offers products and services including NIOX Device and FeNO by NIOX Range. Circassia Pharmaceuticals operates in a competitive market with competitors including BeiGene, Serum Institute of India, BioNTech, Vir Biotechnology and Cidara Therapeutics, among others.
- Headquarter Oxford, United Kingdom
- Employees 128 as on 31 Dec, 2021
- Founders Charles Swingland
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Circassia Pharmaceuticals Plc
-
Annual Revenue
$29.58 M (USD)126as on Dec 31, 2018
-
Net Profit
$-42.36 M (USD)27as on Dec 31, 2018
-
EBITDA
-
Total Equity Funding
$156.6 M (USD)
in 5 rounds
-
Latest Funding Round
$6.21 M (USD), Post-IPO
Jun 02, 2020
-
Investors
Goldman Sachs
& 5 more
-
Employee Count
128
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Circassia Pharmaceuticals
Circassia Pharmaceuticals is a publicly listed company on the LSE with ticker symbol NIOX in UK, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Circassia Pharmaceuticals
Circassia Pharmaceuticals offers a comprehensive portfolio of products and services, including NIOX Device and FeNO by NIOX Range. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Measures FeNO for accurate asthma diagnosis and monitoring.
Supports airway inflammation assessment in asthma care.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Circassia Pharmaceuticals
Circassia Pharmaceuticals has successfully raised a total of $156.6M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.21 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $6.2M
-
First Round
First Round
(01 Jan 2007)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Post-IPO - Circassia Pharmaceuticals | Valuation |
investors |
|
| Apr, 2011 | Amount | Series D - Circassia Pharmaceuticals | Valuation | Invesco Perpetual | |
| Dec, 2009 | Amount | Series C - Circassia Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Circassia Pharmaceuticals
Circassia Pharmaceuticals has secured backing from 6 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Goldman Sachs, Invesco Perpetual and Imperial Innovations. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in startups are focused on Europe and the US.
|
Founded Year | Domain | Location | |
|
Investment banking services are delivered across multiple financial sectors.
|
Founded Year | Domain | Location | |
|
Diversified investment management services are provided globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Circassia Pharmaceuticals
Circassia Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Prosonix. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops inhaled respiratory medicines.
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Circassia Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Circassia Pharmaceuticals Comparisons
Competitors of Circassia Pharmaceuticals
Circassia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, BioNTech, Vir Biotechnology and Cidara Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic proteins are developed for autoimmune and allergic disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Circassia Pharmaceuticals
Frequently Asked Questions about Circassia Pharmaceuticals
When was Circassia Pharmaceuticals founded?
Circassia Pharmaceuticals was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Where is Circassia Pharmaceuticals located?
Circassia Pharmaceuticals is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Is Circassia Pharmaceuticals a funded company?
Circassia Pharmaceuticals is a funded company, having raised a total of $156.6M across 5 funding rounds to date. The company's 1st funding round was a Series C of $25M, raised on Jan 01, 2007.
How many employees does Circassia Pharmaceuticals have?
As of Dec 31, 2021, the latest employee count at Circassia Pharmaceuticals is 128.
What is the annual revenue of Circassia Pharmaceuticals?
Annual revenue of Circassia Pharmaceuticals is $29.58M as on Dec 31, 2018.
What does Circassia Pharmaceuticals do?
Circassia is focused on developing devices for treatment of allergy and respiratory disease. The company has developed NIOX for asthma management and Tudorza to treat chronic obstructive pulmonary disease. The next-generation immunotherapy technology is in phase III testing for cat allergy and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia has also developed FlixotideFlovent substitute and SeretideAdvair substitute. The Company is also developing a number of COPD of treatments, Duaklir US, Spiriva substitute, LABALAMA formulation and COPD therapy formulation.
Who are the top competitors of Circassia Pharmaceuticals?
Circassia Pharmaceuticals's top competitors include BeiGene, BioNTech and Decibel Therapeutics.
What products or services does Circassia Pharmaceuticals offer?
Circassia Pharmaceuticals offers NIOX Device and FeNO by NIOX Range.
Is Circassia Pharmaceuticals publicly traded?
Yes, Circassia Pharmaceuticals is publicly traded on LSE under the ticker symbol NIOX.
How many acquisitions has Circassia Pharmaceuticals made?
Circassia Pharmaceuticals has made 1 acquisition, including Prosonix.
Who are Circassia Pharmaceuticals's investors?
Circassia Pharmaceuticals has 6 investors. Key investors include Goldman Sachs, Invesco Perpetual, Imperial Innovations, Richard Griffiths, and Lansdowne Partners.
What is Circassia Pharmaceuticals's ticker symbol?
The ticker symbol of Circassia Pharmaceuticals is NIOX on LSE.